Deal Watch: Teva/Mylan/Perrigo Speculation Pushes Busy Celgene, AstraZeneca Offstage
Executive Summary
AstraZeneca and its large-molecule affiliate MedImmune will partner with Celgene to develop anti-PD-LI immune checkpoint inhibitor MEDI4736. MedImmune also signed combination trial agreements with Juno and Immunocore, while Celgene arranged to buy Quanticel and Mesoblast.
You may also be interested in...
Novartis Ups The Ante In Immunotherapy With CoStim Buy
The European pharma is increasing its stake in cancer immunotherapy with the acquisition of a start-up biotech that brings over late-stage assets against several targets.
Array Strikes New Deal For Cancer Drug With Longtime Partner Genentech, Taking $28M Upfront
Genentech gains a second compound that regulates cell cycle progression and Array receives cash to advance four in-house drugs through the clinic.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.